Home

Nexalin Technology, Inc. - Common Stock (NXL)

2.8800
0.00 (0.00%)

Nexalin Technology, Inc. is a publicly traded company focused on the development and commercialization of innovative therapeutic technologies designed to improve mental health and wellness

The company specializes in non-invasive neurostimulation therapies that target various mental health conditions, offering potential alternative treatment options. By integrating advanced technology with a commitment to research and development, Nexalin aims to enhance the quality of life for individuals seeking effective solutions to manage their mental health challenges.

SummaryNewsPress ReleasesChartHistoricalFAQ
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET.
By Nexalin Technology, Inc. · Via GlobeNewswire · January 23, 2025
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
DIFS Technology: A Potential Game-Changer for Mental Health Treatments
By Nexalin Technology, Inc. · Via GlobeNewswire · January 14, 2025
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2
By Nexalin Technology, Inc. · Via GlobeNewswire · December 23, 2024
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment
By Nexalin Technology, Inc. · Via GlobeNewswire · November 26, 2024
Nexalin Technology CEO Provides Letter to Shareholders
HOUSTON, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today released a letter to shareholders from its CEO Mark White:
By Nexalin Technology, Inc. · Via GlobeNewswire · November 11, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET.
By Nexalin Technology, Inc. · Via GlobeNewswire · November 1, 2024
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2).
By Nexalin Technology, Inc. · Via GlobeNewswire · November 1, 2024
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Nexalin Technology, Inc. (Nasdaq:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · November 1, 2024
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients
By Nexalin Technology, Inc. · Via GlobeNewswire · October 28, 2024
NASDAQ Stocks Under $1 to Watch in October 2024: LGCB, KAVL, NXL, NXU, FAMI
As the stock market continues to offer exciting opportunities for investors, several NASDAQ-listed companies trading under $1 have caught the eye with their innovative approaches and growth potential. These companies span various industries, from technology to agriculture, offering diverse investment possibilities. Here are five stocks to watch this October:
Via AB Newswire · October 25, 2024
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · October 25, 2024
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model
By Nexalin Technology, Inc. · Via GlobeNewswire · October 22, 2024
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment
By Nexalin Technology, Inc. · Via GlobeNewswire · October 17, 2024
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment
By Nexalin Technology, Inc. · Via GlobeNewswire · October 14, 2024
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions
By Nexalin Technology, Inc. · Via GlobeNewswire · September 5, 2024
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and LOBO EV Technologies Ltd. (Nasdaq:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · July 26, 2024
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA
By Nexalin Technology, Inc. · Via GlobeNewswire · July 18, 2024
Nexalin Technology Announces Closing of $5.2 Million Public Offering
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses were approximately $5,250,000.
By Nexalin Technology, Inc. · Via GlobeNewswire · July 1, 2024
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $5,250,000.
By Nexalin Technology, Inc. · Via GlobeNewswire · June 27, 2024
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.  The newly issued patent entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia,” relates to the Company’s Gen-2 and Gen-3 brain stimulation medical device that administers a proprietary frequency based waveform that is designed to effectively treat patients in a pain free and undetectable manner.
By Nexalin Technology, Inc. · Via GlobeNewswire · June 20, 2024
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · June 14, 2024
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders
By Nexalin Technology, Inc. · Via GlobeNewswire · June 13, 2024
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies.
Via ACCESSWIRE · June 6, 2024
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City.
By Nexalin Technology, Inc. · Via GlobeNewswire · June 4, 2024
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
By Nexalin Technology, Inc. · Via GlobeNewswire · June 3, 2024